Victor Carabello, MD
Nephrology · Los Angeles, CANPI 1649293705
Payments from drug & device makers
Across 1,698 payments — averaging $832.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$996K
- Amgen$161K
- Novo Nordisk$66K
- Bayer$62K
- Merck$35K
- ANI Pharmaceuticals, Inc.$34K
- plus $61K from 42 others
What the payments were for
- Consulting fees$11,1003%
- Speaking & faculty fees$273,53575%
- Travel & lodging$39,91211%
- Food & beverage$37,98110%
- Education$9170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,414,310 in reported general payments places this provider in the 95th percentile of 1,341 nephrology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 78 | $4,392,908 |
| CortrophinCorticotropin | 43 | $2,425,092 |
| KerendiaFinerenone | 894 | $597,125 |
| JardianceEmpagliflozin | 418 | $284,820 |
| RybelsusSemaglutide | 260 | $276,591 |
| FarxigaDapagliflozin Propanediol | 394 | $264,428 |
| LokelmaSodium Zirconium Cyclosilicate | 300 | $243,025 |
| AuryxiaFerric Citrate | 201 | $221,222 |
| Repatha SureclickEvolocumab | 356 | $195,337 |
| MounjaroTirzepatide | 124 | $123,643 |
| RayaldeeCalcifediol | 107 | $121,286 |
| VeltassaPatiromer Calcium Sorbitex | 110 | $107,548 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 109 | $90,680 |
| VelphoroSucroferric Oxyhydroxide | 39 | $84,019 |
| XphozahTenapanor Hcl | 23 | $80,690 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa, Epogen, Aranesp | $160,759 | $4,449,204175 claims |
| BayerKerendia | $62,365 | $597,125894 claims |
| AstraZenecaFarxiga, Lokelma | $2,220 | $507,454694 claims |
| Novo NordiskRybelsus, Ozempic, Xultophy 100-3.6 | $65,532 | $368,672360 claims |
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr | $568 | $301,488449 claims |
| Akebia Therapeutics IncAuryxia | $1,763 | $221,222201 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $791 | $187,421235 claims |
| OPKO Pharmaceuticals, LLCRayaldee | $552 | $121,286107 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $1,208 | $90,680109 claims |
| Fresenius USA Marketing, Inc.Velphoro | $967 | $84,01939 claims |
| AbbVieLinzess | $13 | $46,83683 claims |
| Johnson & JohnsonProcrit, Invokana | $106 | $40,06959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,341 nephrology providers in California.
Other nephrology in Los Angeles
- Anjay RastogiLos Angeles$6.3M
- Mohamed El-ShahawyLos Angeles$4.4M
- Suphamai BunnapradistLos Angeles$1.7M
- John SimLos Angeles$1.3M
- Tariq ShahLos Angeles$1.2M
- Michael LevineLos Angeles$867K
- Aamir JamalSan Dimas$5.5M
- Kalpesh PatelCalabasas$3.6M
- Jehad HaggiagiMission Hills$3.6M
- Malvin YanSouth Gate$3.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.